The Year In Biotech/Biodiversity: Patentability, Plant Varieties, Treaty Implementation 16/02/2015 by Catherine Saez, Intellectual Property Watch 1 Comment Intellectual property-related developments expected this year could profoundly impact the fields of biotechnology and biodiversity. In addition, ongoing issues relating to plant variety protection and public health are expected to be at the forefront of discussions this year. The following is a look at many of the top issues to come.
Gilead To Appeal India Patent Rejection, Hails Regulatory Approval 16/01/2015 by William New, Intellectual Property Watch 2 Comments Pharmaceutical manufacturer Gilead has given its side to this week’s story of the rejection of its patent on a hepatitis C treatment in India, and it insists it will prevail in making its medicines available in India on its terms.
Key Hepatitis C Patent Rejected In India 14/01/2015 by William New, Intellectual Property Watch 10 Comments Today’s rejection by the Patent Office Controller of India of a patent application by Gilead company for a key drug against hepatitis C is being hailed by advocates as a path to dramatically lower costs of treatment for the disease. Hepatitis C has been noteworthy for exorbitantly priced medicines over the past year. A look at the decision shows that a provision in India’s law continues to stop patent applications if they fail to show sufficient novelty and inventive step – and are subject to opposition.
Report Explains Rapid Rise In Chinese Patents; Compares Innovation Quotient 11/12/2014 by William New, Intellectual Property Watch 10 Comments China has been filing patents at far greater rates than any other nation on earth in recent years. This week, a Thomson Reuters report broke down that growth and compared it with other leading nations on the basis of innovation.
EPO Supervisory Body To Face Fears Over Patent Quality, Judicial Independence 10/12/2014 by Dugie Standeford for Intellectual Property Watch 4 Comments As staff strikes continue and the European Patent Office’s Administrative Council prepares for what could be a contentious 11 December meeting, opinions are split over the effect of the turmoil on the office’s role in Europe’s unitary patent.
Civil Society Files Opposition To Monsanto Climate-Related Soybean Patent 03/12/2014 by Catherine Saez, Intellectual Property Watch 2 Comments A civil society coalition is after one of European Monsanto’s patents, accusing the giant seed corporation of biopiracy. The patent granted in February was challenged by the No Patents on Seeds coalition, which filed an opposition a few days ago.
Medicines Patent Pool Adds Two AbbVie Paediatric HIV Medicines 01/12/2014 by William New, Intellectual Property Watch 1 Comment The Medicines Patent Pool (MPP) has announced a licence agreement with pharmaceutical manufacturer AbbVie to allow the production of cheaper, more accessible paediatric versions of two HIV medicines.
China Establishes Patent, Trademark And Copyright Integrated Office 28/11/2014 by Mingjiang Liu for Intellectual Property Watch Leave a Comment China has set up an administrative office called the Shanghai City Pudong New Area Intellectual Property Office, integrating patent, trademark and copyright administration in the Pudong New Area in Shanghai city.
Index: Pharma Industry Improves On Access To Medicines, Needs Work On Ethics, Patent Disclosure 17/11/2014 by William New, Intellectual Property Watch Leave a Comment The 2014 edition of an independent ranking of leading pharmaceutical companies’ efforts to help developing countries released today found new initiatives undertaken in the past two years. But it said corruption and insufficient disclosure of existing patents continue to plague the industry.
Global Differences On Patents Lead WIPO Patent Law Committee To Stumble On Future Work 10/11/2014 by Catherine Saez, Intellectual Property Watch 3 Comments Once again, differences over the role of a World Intellectual Property Organization committee last week came in the way of consensus and prevented delegates from agreeing on future work. At the heart of the discontent was the perceived imbalance of the proposed programme of work, which some said disregarded the interests of developing countries. A speaker for the African region gave a striking speech on the Ebola crisis as an example of the failure of the patent system.